A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

Overview

This randomized, open-label, multicenter study will evaluate the efficacy and safety of navitoclax in addition to bendamustine and rituximab in patients with relapsed diffuse large B-cell lymphoma. Patients will be randomized to receive navitoclax in addition to bendamustine and rituximab or bendamustine and rituximab alone for 6 cycles.

Full Title of Study: “A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2014

Interventions

  • Drug: bendamustine
    • Intravenous repeating dose\n
  • Drug: navitoclax
    • Oral repeating dose\n
  • Drug: rituximab
    • Intravenous repeating dose\n

Arms, Groups and Cohorts

  • Active Comparator: A
  • Experimental: B

Clinical Trial Outcome Measures

Primary Measures

  • Progression-free survival (time from randomization to progression, relapse or death of any cause)
    • Time Frame: up to approximately 33 months

Secondary Measures

  • Clinical response rates (complete response/partial response/stable disease)
    • Time Frame: approximately 33 months
  • Duration of response
    • Time Frame: approximately 33 months
  • Overall survival
    • Time Frame: approximately 33 months
  • Safety: Incidence of adverse events
    • Time Frame: approximately 33 months

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically documented diagnosis of diffuse large B-cell lymphoma – Patients must have relapsed or developed progressive disease following salvage therapy, or must have relapsed or progressed following initial therapy and in the opinion of the investigator are medically unfit to receive high dose chemotherapy with autologous stem cell transplant (SCT) or other salvage therapy of higher priority – Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2 – Patients who have undergone STC must be more than 100 days from autologous stem cell infusion prior to first dose of study drug, must have recovered from any transplant related toxicity and must have adequate bone marrow function as defined by protocol independent of any growth factor support – Patients who have not undergone SCT must have adequate bone marrow function as defined by protocol independent of any growth factor support – Adequate coagulation, renal and hepatic function Exclusion Criteria:

  • Refractory DLBCL – History of other malignancies within 2 years prior to initiation of study treatment except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, low-grade localized prostate cancer treated surgically with curative intent or one that carries a good prognosis, in situ ductal carcinoma of the breast treated with lumpectomy (with and without radiation) with curative intent – Active infection requiring parenteral antibiotics or antiviral or antifungal agents – Inherited or acquired bleeding diathesis, anticoagulant drugs or drugs that inhibit platelet function, underlying conditions that predisposes to abnormal bleeding, or refractoriness to platelet transfusions – Clinically significant cardiovascular disease, New York Heart Association Grade II or greater congestive heart failure, or ventricular tachyarrhythmias requiring medication within 1 year prior to the initiation of study treatment – Positive for hepatitis B, hepatitis C or HIV infection

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Genentech, Inc.
  • Collaborator
    • AbbVie (prior sponsor, Abbott)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Clinical Trials, Study Director, Genentech, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.